AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29847665 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone hydrogel lenses with Dk/t range of 31 to 211 units
Number of subjects: 29
Study 29847665 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral eye without lens)
Number of subjects: 29
Study 29847665 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone hydrogel lenses
Number of subjects: 29
Study 28542926 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/d
Number of subjects: 80
Study 28542926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 25628173 — intervention group
Group type: EXPERIMENTAL
Intervention: Hi-HiLo (living high and training high and low for 4 weeks)
Number of subjects: 54
Study 25628173 — intervention group
Group type: EXPERIMENTAL
Intervention: Hi-Hi (living and training at moderate altitude for 3 and 4 weeks)
Number of subjects: 54
Study 25628173 — intervention group
Group type: COMPARATOR
Intervention: SL (living and training at sea level for 4 weeks)
Number of subjects: 54
Study 22390966 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease targeting therapies (DTT)
Number of subjects: 79
Study 22390966 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalation of therapy
Number of subjects: 79
Study 21681698 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Number of subjects: 37
Study 21681698 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 37
Study 19389004 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg on-demand 0.75-2 hours before sexual stimulation
Number of subjects: 266
Study 19389004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 16774799 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental oral nutrition supplements
Number of subjects: 50
Study 16774799 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide oral nutrition supplements
Number of subjects: 50
Study 16774799 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric oral nutrition supplements
Number of subjects: 50
Study 16774799 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (N=50)
Number of subjects: 50
Study 16774799 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 50
Study 15319723 — intervention group
Group type: EXPERIMENTAL
Intervention: MISTELS simulator practice (transfer drill) for 4 weeks
Number of subjects: 215
Study 15319723 — intervention group
Group type: COMPARATOR
Intervention: No practice of the transfer drill
Number of subjects: 215
Study 15319723 — intervention group
Group type: EXPERIMENTAL
Intervention: MISTELS scores
Number of subjects: 215
Study 11207404 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg intramuscularly
Number of subjects: 30
Study 11207404 — intervention group
Group type: COMPARATOR
Intervention: Meperidine 1.5 mg/kg (max 100 mg) intramuscularly
Number of subjects: 30
Study 9278654 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (loading dose of 2 x 10(6) KI units followed by 0.5 x 10(6) KI units/h)
Number of subjects: 136
Study 9278654 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 136
Study 8472112 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 113
Study 8472112 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Number of subjects: 113
Study 8472112 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Ultrasound and Computed Tomography
Number of subjects: 113
Study 8472112 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound and Computed Tomography
Number of subjects: 113
Study 3725504 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat emulsion administered at a constant rate for 24 hours, starting at 1 g/kg and increasing to a maximum of 4 g/kg
Number of subjects: 41
Study 3725504 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat emulsion administered at a constant rate for 16 hours, starting at 1 g/kg and increasing to a maximum of 4 g/kg
Number of subjects: 41
Study 3725504 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat emulsion administered at a constant rate of 4 g/kg for 24 hours
Number of subjects: 41
Study 3725504 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion rates as used in the study
Number of subjects: 41
Study 3725504 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of fat at a constant rate for 24 hours
Number of subjects: 41
Study 30462279 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued DOAC (dabigatran, rivaroxaban, or apixaban)
Number of subjects: 662
Study 30462279 — intervention group
Group type: COMPARATOR
Intervention: Interrupted DOAC (dabigatran, rivaroxaban, or apixaban)
Number of subjects: 662
Study 26698676 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertility medication (selective estrogen receptor modulator, gonadotropin, or other) or infertility treatment (IVF or IUI)
Number of subjects: 941
Study 24584875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT)
Number of subjects: 0
Study 24584875 — intervention group
Group type: COMPARATOR
Intervention: Standard external beam radiation therapy (EBRT)
Number of subjects: 0
Study 23235414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin
Number of subjects: 60
Study 23235414 — intervention group
Group type: COMPARATOR
Intervention: Piracetam
Number of subjects: 60
Study 20926027 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin C (0.06 g/kg bolus followed by 0.02 g/kg)
Number of subjects: 32
Study 20926027 — intervention group
Group type: COMPARATOR
Intervention: Control (no intra-operative vitamin C)
Number of subjects: 32
Study 17432646 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion
Number of subjects: 80
Study 17432646 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture plus TDP radiation
Number of subjects: 80
Study 15818529 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute day hospital care
Number of subjects: 144
Study 15818529 — intervention group
Group type: COMPARATOR
Intervention: Inpatient care
Number of subjects: 144
Study 12196880 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal misoprostol (400 microg)
Number of subjects: 240
Study 12196880 — intervention group
Group type: COMPARATOR
Intervention: Parenteral oxytocin (5 units i.v. or 10 units i.m.)
Number of subjects: 240
Study 12196880 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes (excessive third stage bleeding, duration of third stage of labour, need for manual removal of the placenta or the need for additional oxytocics)
Number of subjects: 240
Study 10223249 — intervention group
Group type: EXPERIMENTAL
Intervention: CA125 elevation (> or =30 U/mL)
Number of subjects: 1542
Study 10223249 — intervention group
Group type: COMPARATOR
Intervention: CA125 <30 U/mL
Number of subjects: 1542
Study 8697999 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial esophagectomy, partial gastrectomy and end‐to‐side esophagogastric anastomosis with fundoplication
Number of subjects: 193
Study 8697999 — intervention group
Group type: COMPARATOR
Intervention: End‐to‐end esophagogastrostomy
Number of subjects: 193
Study 2129633 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg omeprazole o.m.
Number of subjects: 48
Study 2129633 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole o.m.
Number of subjects: 48
Study 2129633 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole o.m.
Number of subjects: 48
Study 2129633 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine b.d.
Number of subjects: 48
Study 2129633 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of omeprazole
Number of subjects: 48
Study 2129633 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 48
Study 2129633 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-induced hypochlorhydria
Number of subjects: 48
Study 34336 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenoceptor blockade during anaesthesia
Number of subjects: 26
Study 31973744 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed cash payment incentive
Number of subjects: 1740
Study 31973744 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery payment incentive
Number of subjects: 1740
Study 31973744 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1740
Study 30593693 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat stress (32 ± 2°C)
Number of subjects: 48
Study 30593693 — intervention group
Group type: COMPARATOR
Intervention: Normal temperature (20 ± 2°C)
Number of subjects: 48
Study 28231372 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal bipolar radiofrequency turbinate volume reduction (RFTVR)
Number of subjects: 30
Study 28231372 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency-assisted turbinectomy (RFaT)
Number of subjects: 30
Study 25981966 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher produce environment
Number of subjects: 0
Study 25981966 — intervention group
Group type: EXPERIMENTAL
Intervention: Better neighborhood access to produce
Number of subjects: 0
Study 23692526 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg
Number of subjects: 0
Study 23692526 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 100 mg
Number of subjects: 0
Study 23692526 — intervention group
Group type: COMPARATOR
Intervention: Mirabegron 25 mg
Number of subjects: 0
Study 23692526 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg
Number of subjects: 0
Study 23692526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21247663 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquaphor Healing Ointment (AHO)
Number of subjects: 20
Study 21247663 — intervention group
Group type: COMPARATOR
Intervention: Polysporin first‐aid ointment (Poly/Bac)
Number of subjects: 20
Study 19570440 — intervention group
Group type: EXPERIMENTAL
Intervention: Motherwort injection (40 mg uterine injection during CS and 20 mg intramuscular injection per 12 hours 3 times after CS)
Number of subjects: 440
Study 19570440 — intervention group
Group type: EXPERIMENTAL
Intervention: Motherwort + Oxytocin (40 mg motherwort and 10 U oxytocin uterine injection during CS; 20 mg motherwort intramuscular injection per 12 hours 3 times after CS)
Number of subjects: 440
Study 19570440 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (10 U uterine injection and 10 U+5% glucose 500 ml intravenously during operation; 10 U intramuscular injection per 12 hours 3 times after CS)
Number of subjects: 440
Study 19570440 — intervention group
Group type: EXPERIMENTAL
Intervention: Motherwort injection
Number of subjects: 440
Study 19570440 — intervention group
Group type: EXPERIMENTAL
Intervention: Motherwort + Oxytocin
Number of subjects: 440
Study 19570440 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 440
Study 17522285 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-based academic detailing intervention involving a physician, nurse, and office manager delivering educational presentations and developing action plans.
Number of subjects: 0
Study 17522285 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-based academic detailing intervention
Number of subjects: 0
Study 15928300 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 Gy in one treatment fraction
Number of subjects: 898
Study 15928300 — intervention group
Group type: COMPARATOR
Intervention: 30 Gy in 10 treatment fractions
Number of subjects: 898
Study 12711105 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 25 mg base/kg given unsupervised by mothers at home
Number of subjects: 0
Study 12711105 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine 25 mg base/kg given supervised at a health centre
Number of subjects: 0
Study 10472159 — intervention group
Group type: EXPERIMENTAL
Intervention: lifestyle physical activity
Number of subjects: 38
Study 10472159 — intervention group
Group type: COMPARATOR
Intervention: traditional aerobic activity
Number of subjects: 38
Study 8911949 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine TDS (30 mg)
Number of subjects: 24
Study 8911949 — intervention group
Group type: COMPARATOR
Intervention: Placebo TDS
Number of subjects: 24
Study 1921686 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (180 mg) and Propranolol (80 mg)
Number of subjects: 17
Study 1921686 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug (Diltiazem and Propranolol) after placebo
Number of subjects: 17
Study 1921686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 7029290 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (ADR) 30 mg/m2/day for 3 successive days every 4 weeks for 6 courses
Number of subjects: 62
Study 7029290 — intervention group
Group type: COMPARATOR
Intervention: Alternating Adriamycin (ADR) and high-dose methotrexate followed by citrovorum factor rescue (HDMTX-CFR)
Number of subjects: 62
Study 30590813 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 274
Study 30590813 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 274
Study 30590813 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab up-titrators (n=25)
Number of subjects: 274
Study 30590813 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 274
Study 27707001 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of fentanyl citrate and propofol lipid emulsion (PLE)
Number of subjects: 0
Study 27707001 — intervention group
Group type: COMPARATOR
Intervention: Sequential administration of fentanyl citrate and propofol lipid emulsion (PLE)
Number of subjects: 0
Study 26376528 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyramidalis muscle left attached to the rectus muscles (Group I)
Number of subjects: 108
Study 26376528 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservation of the connection between the pyramidalis muscle and the rectus sheath (Group II)
Number of subjects: 108
Study 26376528 — intervention group
Group type: COMPARATOR
Intervention: Group I (Control)
Number of subjects: 108
Study 24912398 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive counselling
Number of subjects: 280
Study 23072077 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung meridian acupoint group (group A)
Number of subjects: 52
Study 23072077 — intervention group
Group type: EXPERIMENTAL
Intervention: Large intestine meridian acupoint group (group B)
Number of subjects: 52
Study 23072077 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung and large intestine meridian acupoint group (group C)
Number of subjects: 52
Study 23072077 — intervention group
Group type: COMPARATOR
Intervention: Control group (Ventolin aerosol)
Number of subjects: 52
Study 23072077 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between group B and group C
Number of subjects: 52
Study 18564281 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% capsaicin gel applied once daily for 5 months
Number of subjects: 100
Study 18564281 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control) applied once daily for 5 months
Number of subjects: 100
Study 18564281 — intervention group
Group type: COMPARATOR
Intervention: Aged group (older than 65 years)
Number of subjects: 100
Study 17482520 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 28
Study 17482520 — intervention group
Group type: COMPARATOR
Intervention: Valproate
Number of subjects: 28
Study 15022445 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic recanalization under transrectal ultrasonic control
Number of subjects: 242
Study 15022445 — intervention group
Group type: COMPARATOR
Intervention: Open reconstructive-plastic operations
Number of subjects: 242
Study 12220694 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 (1500 microg/day)
Number of subjects: 191
Study 12220694 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/day)
Number of subjects: 191
Study 12220694 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with folic acid and vitamin B12
Number of subjects: 191
Study 9766695 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone hydrochloride
Number of subjects: 8
Study 9766695 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 8
Study 9766695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7709405 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 19755 (1.5 mg/kg)
Number of subjects: 32
Study 7709405 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 19755 (2 mg/kg)
Number of subjects: 32
Study 7709405 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 19755 (1.75 mg/kg)
Number of subjects: 32
Study 7709405 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 19755 (1.0 mg/kg)
Number of subjects: 32
Study 7709405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 7709405 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 19755 (all doses)
Number of subjects: 32
Study 2676792 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine
Number of subjects: 100
Study 2676792 — intervention group
Group type: COMPARATOR
Intervention: 0.75% bupivacaine/2% mepivacaine
Number of subjects: 100
Study 2676792 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine with 75 IU hyaluronidase
Number of subjects: 100
Study 620896 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon, 2 mg given intravenously before aspirin instillation
Number of subjects: 27
Study 620896 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon, 2 mg given intravenously
Number of subjects: 27
Study 620896 — intervention group
Group type: COMPARATOR
Intervention: Aspirin, 600 mg suspended in 100 ml of isotonic saline
Number of subjects: 27
Study 31703934 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV-Al
Number of subjects: 1002
Study 31703934 — intervention group
Group type: COMPARATOR
Intervention: IPV
Number of subjects: 1002
Study 31200945 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral protein supplementation (30 grams of whey, three days/week during dialysis)
Number of subjects: 138
Study 31200945 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein plus exercise (30-45 minutes of cycling during dialysis treatment, three days/week)
Number of subjects: 138
Study 31200945 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 138
Study 31200945 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein and protein plus exercise groups
Number of subjects: 138
Study 28877027 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (18 μg once daily)
Number of subjects: 841
Study 28877027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 841
Study 25042896 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes management (using HbA1C as the indicator)
Number of subjects: 5900
Study 25042896 — intervention group
Group type: EXPERIMENTAL
Intervention: Occasional opium use
Number of subjects: 5900
Study 25042896 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression and anxiety in diagnosed diabetes
Number of subjects: 5900
Study 25042896 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes management effectiveness
Number of subjects: 5900
Study 25042896 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight and obesity
Number of subjects: 5900
Study 25042896 — intervention group
Group type: EXPERIMENTAL
Intervention: Low physical activity
Number of subjects: 5900
Study 22901550 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk intakes
Number of subjects: 227
Study 22901550 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intakes
Number of subjects: 227
Study 22901550 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D
Number of subjects: 227
Study 21104227 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (35 mg weekly)
Number of subjects: 194
Study 21104227 — intervention group
Group type: COMPARATOR
Intervention: Elcatonin (intramuscular 20 units a week)
Number of subjects: 194
Study 19059753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy with Attention Training (CBGT + ATT)
Number of subjects: 81
Study 19059753 — intervention group
Group type: COMPARATOR
Intervention: Relaxation Training (RT)
Number of subjects: 81
Study 17090233 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance respirometry
Number of subjects: 80
Study 17090233 — intervention group
Group type: COMPARATOR
Intervention: Control (oesophageal intubation)
Number of subjects: 80
Study 15509131 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg and HCTZ 12.5 mg once daily (n=46)
Number of subjects: 92
Study 15509131 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg alone once daily (n=46)
Number of subjects: 92
Study 11345748 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (group S)
Number of subjects: 104
Study 11345748 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group P)
Number of subjects: 104
Study 11345748 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with premedication (group MS)
Number of subjects: 104
Study 11345748 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with premedication (group MP)
Number of subjects: 104
Study 11345748 — intervention group
Group type: COMPARATOR
Intervention: All groups (S, P, MS, MP)
Number of subjects: 104
Study 9128126 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis relaxation techniques
Number of subjects: 32
Study 9128126 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 32
Study 7953396 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat cytology
Number of subjects: 60
Study 7953396 — intervention group
Group type: COMPARATOR
Intervention: Core biopsy
Number of subjects: 60
Study 3316516 — intervention group
Group type: EXPERIMENTAL
Intervention: Polychemotherapy as initial therapy
Number of subjects: 0
Study 3316516 — intervention group
Group type: COMPARATOR
Intervention: Single new drug
Number of subjects: 0
Study 31272939 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 69
Study 31272939 — intervention group
Group type: COMPARATOR
Intervention: Pazopanib
Number of subjects: 69
Study 30227659 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocovid 200 mg twice a day
Number of subjects: 45